



# Bukwang Pharmaceutical Co., Ltd.

Bukwang, founded in 1960, is dedicated to bringing novel and outstanding medicines to the public.

As in-house developed products, Levovir® was developed as the 4th new drug in the world for hepatitis B and licensed out to Asia. Dexid® was developed for the treatment of diabetic neuropathy and is to be exported to East-Asia.

Bukwang has been actively investing in R&D, and continuing to pursue new drug development with various partners worldwide.

## Main Products



Levovir®



Dexid®

Product (ingredient/formulation)	Indication	Exporting countries	Remarks
Levovir® capsule (Clevudine)	Chronic hepatitis B virus infection	Philippines	Launched
Dexid® tablet (R-thioctic acid tromethamine)	Diabetic polyneuropathy	East-Asian countries	Launched

CEO  
Hee-Won Yoo

Location  
7, Sangdo-ro, Dongjak-gu, Seoul, Korea

Specialty  
1. CNS Small molecules  
2. Metabolic disorder Small molecules  
3. Oncology Small molecules (including IMDs)

Tel / Fax / E-mail  
T. 82-2-8288-114  
F. 82-2-8288-029

## R&D Pipeline

TA	Project	Indication	Category	Development phase				
				Discovery	Preclinical	Phase I	Phase II	Phase III
CNS	Lurasidone	Schizophrenia/ bipolar depression	Chemical	[Progress bar]				[Progress bar]
Metabolism	MLR-1023	T2DM		[Progress bar]				
CNS	JM-010	Dyskinesia		[Progress bar]				
Oncology	SOL-804	Prostate cancer		[Progress bar]				
Immunology	BKC-1501A	Immune disorders		[Progress bar]				
Metabolism	BK-1701	Anti-diabetes/ Obesity		[Progress bar]				
CNS	USP8 Program	Neurodegeneration		[Progress bar]				
I-O	AhR inhibitor	Cancers		[Progress bar]				
CNS	PKR inhibitor	Neurodegeneration		[Progress bar]				